Expression of p53 and TP53 Mutational Analysis in Malignant Neoplasms Arising in Preexisting Spiradenoma, Cylindroma, and Spiradenocylindroma, Sporadic or Associated with Brooke-Spiegler Syndrome
- 1 May 2010
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Dermatopathology
- Vol. 32 (3), 215-221
- https://doi.org/10.1097/dad.0b013e3181b9678c
Abstract
We performed immunohistochemical assessment of p53 expression and TP53 mutational analysis of 15 malignant neoplasms arising from preexisting benign cylindroma, spiradenoma, and spiradenocylindroma, sporadic or associated with Brooke-Spiegler syndrome. At least weak and focal p53 positivity was present in 13 of the 15 lesions. Successful PCR and sequencing were possible in 12 of the 15 cases. In one case only there were 2 p53 mutations, one being a c.673-1G>A splice-site mutation in the 3'-end of intron 6 (position--g.15289G>A, contig gb.AY838696.1) and the second being a c.743G>A (p.R248Q) mutation in exon 7 (position--15360G>A, contig gb.AY838696.1). Single nucleotide polymorphisms were detected in all 12 malignant cases analyzed. As a control group, we included 12 randomly selected sporadic cases of spiradenoma (n = 5), cylindroma (n = 4), and spiradenocylindroma (n = 3). None of the 12 benign control group cases harbored a TP53 mutation, whereas all 12 demonstrated single nucleotide polymorphisms identical to those detected in the malignant tumor group. Immunohistochemically, 1 cylindroma and 2 spiradenomas demonstrated weak and focal p53 positivity. In conclusion, we found a fairly high rate of p53 expression in malignant neoplasms arising from preexisting benign spiradenomas, cylindromas, and spiradenocylindromas. However, the mutation rate of TP53 was low. Whereas immunostaining for p53 has been suggested as an adjunct tool to differentiate benign spiradenoma, cylindroma, and spiradenocylindroma from their malignant counterparts, its utility is limited by its heterogeneous pattern of expression, especially the sometimes lack of staining in clearly malignant areas and the occurrence of focal, weak positivity in the benign residua or in unequivocally benign neoplasms.Keywords
This publication has 10 references indexed in Scilit:
- Morphologic Diversity of Malignant Neoplasms Arising in Preexisting Spiradenoma, Cylindroma, and Spiradenocylindroma Based on the Study of 24 Cases, Sporadic or Occurring in the Setting of Brooke-Spiegler SyndromeThe American Journal of Surgical Pathology, 2009
- Cutaneous Hidradenocarcinoma: A Clinicopathological, Immunohistochemical, and Molecular Biologic Study of 14 Cases, Including Her2/neu Gene Expression/Amplification, TP53 Gene Mutation Analysis, and t(11;19) TranslocationThe American Journal of Dermatopathology, 2009
- A comparison between p53 accumulation determined by immunohistochemistry andTP53mutations as prognostic variables in tumours from breast cancer patientsActa Oncologica, 2008
- Wild-Type p53 Overexpression and Its Correlation With MDM2 and p14ARF Alterations: An Alternative Pathway to Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Spiradenocylindrocarcinoma: a malignant hybrid tumorJournal of Cutaneous Pathology, 2004
- The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer riskInternational Journal of Cancer, 2002
- The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcomeInternational Urology and Nephrology, 2002
- Hot-spot mutants of p53 core domain evince characteristic local structural changesProceedings of the National Academy of Sciences of the United States of America, 1999
- Malignant eccrine spiradenoma with florid squamous differentiationJournal of Korean Medical Science, 1998
- Malignant eccrine spiradenoma with carcinomatous and sarcomatous elements.Journal of Clinical Pathology, 1997